bixalomer profile

bixalomer: a gastrointestinal agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	25212181
MeSH ID	M000595869

Synonym
D09586
851373-13-2
bixalomer (jan/usan/inn)
bixalomer
2-(chloromethyl)oxirane;n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine

Research Excerpts

Overview

Bixalomer is a nonabsorbable polymer that binds phosphate in the gastrointestinal tract and lowers the serum phosphate level by inhibiting phosphate absorption. It has been clinically available in Japan recently.

Excerpt	Reference	Relevance
"Bixalomer is a nonabsorbable polymer that binds phosphate in the gastrointestinal tract and lowers the serum phosphate level by inhibiting phosphate absorption. "	( Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients. Akizawa, T; Kameoka, C; Kaneko, Y; Kawasaki, S, 2013)	2.09
"Bixalomer is a nonabsorbable polymer that decreases serum phosphate levels by binding phosphate in the gastrointestinal tract."	( Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Akizawa, T; Kameoka, C; Kaneko, Y; Kawasaki, S; Origasa, H, 2014)	1.41
"Bixalomer (Bix) is an amine-functional polymer, non-calcium-containing phosphate (P) binder, and has been clinically available in Japan recently. "	( Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ito, K; Kumata, C; Matsuzaka, K; Nakajima, Y; Ogata, H; Shishido, K; Takeshima, A; Wakasa, M, 2014)	2.12

Toxicity

Excerpt	Reference	Relevance
" Most adverse events (AEs) occurred in the first 12 weeks of treatment."	( Long-Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis. Akizawa, T; Kameoka, C; Kuroishi, K; Tsukada, J; Yamaguchi, Y, 2017)	0.74

Dosage Studied

The P binder was switched from sevelamer hydrochloride to the same dosage of bixalomer. The concentrations of serum P, corrected calcium (Ca) and whole parathyroid hormone (PTH) before and one month after the switch were compared.

Excerpt	Relevance	Reference
" Regarding the results after switching to bixalomer and starting treatment using the same dosage as the dosage previously used for sevelamer hydrochloride, there were many cases that showed increasing P concentrations that required increasing the dosage of bixalomer, the dosage after switching was increased significantly (P=0."	( Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients. Furukawa, K; Ikawa, T; Kato, K; Takahashi, J; Ueno, M; Yokoi, S; Yokouchi, S, 2014)	0.92
" In our study, for 21 cases of maintenance hemodialysis patients undergoing treatment with sevelamer hydrochloride at our hospital, the P binder was switched from sevelamer hydrochloride to the same dosage of bixalomer, and the concentrations of serum P, corrected calcium (Ca) and whole parathyroid hormone (PTH) before and one month after the switch were compared."	( Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride. Gen, S; Ikeda, N; Nobe, K; Nodaira, Y; Saito, K; Sasaki, T, 2014)	0.85
" The initial dosage of bixalomer was set as 1500 mg/day for new administration patients and dosage equivalent to that of the previously-used P binder for patients who were switched to bixalomer."	( Clinical experiences of bixalomer usage at our hospital. Ban, A; Funao, K; Furumitsu, Y; Hata, K; Inoue, K; Makino, R; Okamura, M; Shima, H; Sugita, S; Yoshimoto, M, 2014)	1.02
" These patients tended to have increased levels of serum calcium, hematocrit, and serum ferritin; a decreased number of phosphate binder tablets (from 21 tablets/d to 8 tablets/d); and a decreased dosage of erythropoiesis-stimulating agents."	( [Low Continuity Rate of Sucroferric Oxyhydroxide among Japanese Hemodialysis Patients with High Phosphate Binder Pill Burden]. Mitsuboshi, S; Nagai, K; Okajima, H; Yamada, H, 2018)	0.48

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	17 (100.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (23.53%)	5.53%
Reviews	2 (11.76%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	2 (11.76%)	0.25%
Other	9 (52.94%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
hydrogen carbonate Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.	2.1	1	0	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
phosphoric acid phosphoric acid: concise etchant is 37% H3PO4. phosphoric acid : A phosphorus oxoacid that consists of one oxo and three hydroxy groups joined covalently to a central phosphorus atom.	3.18	1	0	phosphoric acids	algal metabolite; fertilizer; human metabolite; NMR chemical shift reference compound; solvent
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	3.95	3	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
limestone Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.	2.54	2	0	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
lanthanum [no description available]	3.65	2	0	f-block element atom; lanthanoid atom; scandium group element atom
ferric citrate ferric citrate: RN given refers to Fe(+3)[1:1] salt. iron(III) citrate : An iron chelate resulting from the combination of iron(3+) and citrate(3-).	2.17	1	0	iron chelate	anti-anaemic agent; nutraceutical
lanthanum carbonate lanthanum carbonate: a phosphate binder used for hyperphosphatemia treatment in end-stage renal disease	3.65	2	0
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	10.78	7	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
ferric oxide, saccharated Ferric Oxide, Saccharated: A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical.	3.95	3	0

Condition	Relationship Strength	Studies	Trials
Chronic Kidney Diseases [description not available]	7.74	7	2
Coronary Heart Disease [description not available]	3	1	0
Secondary Hyperparathyroidism [description not available]	3	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	3	1	0
Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.	3	1	0
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	7.74	7	2
Hyperphosphatemia A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.	8.98	14	4
Metabolic Acidosis [description not available]	3.89	2	1
Cholera Infantum [description not available]	4.17	3	1
Acidosis A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.	3.89	2	1
Chronic Kidney Failure [description not available]	4.87	7	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	4.87	7	1
Colonic Inertia Symptom characterized by the passage of stool once a week or less.	2.5	2	0
Indigestion [description not available]	2.1	1	0
Esophageal Reflux [description not available]	2.5	2	0
Colicky Pain [description not available]	2.5	2	0
Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.	2.5	2	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	2.1	1	0
Dyspepsia Impaired digestion, especially after eating.	2.1	1	0
Gastroesophageal Reflux Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.	2.5	2	0
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	2.5	2	0

bixalomer

Description

Cross-References

Synonyms (5)

Research Excerpts

Overview

Toxicity

Dosage Studied

Research

Studies (17)

Market Indicators

Research Demand Index: 24.75

Study Types

bixalomer

Description

Cross-References

Synonyms (5)

Research Excerpts

Overview

Toxicity

Dosage Studied

Research

Studies (17)

Market Indicators

Research Demand Index: 24.75

Study Types

Related Drugs (9)

Related Conditions (21)